PDCD1 and non-small cell lung carcinoma: The development of immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) checkpoint inhibitors, has significantly changed the treatment strategy for NSCLC.